Peptid vaccination against PD-L1 in Multiple Myeloma

BestPractice | Jun 2019 | EHA 2019 |

In this MEDtalk Nicolai Grønne Jørgensen present the data from a single center first-in-human study which included patients from four weeks to one year after high dose chemotherapy with autologous stem cell support (HDT).  The results shows, that vaccinations with the PD-L1 peptide (IO103) was associated with very limited side effects and that the vaccine is highly immunogenic